Von Willebrand disease

BioTek reMEDys Promotes Awareness and Education for Bleeding Disorders Awareness Month

Retrieved on: 
Wednesday, March 20, 2024
Research, Infectious Diseases, Public Policy, Government, Healthcare Reform, Biotechnology, Health, Pharmaceutical, General Health, Science, Diagnosis, Coagulopathy, Haemophilia, Caregiver, Education, Patient, Von Willebrand disease, Pharmacist, Blood, Physician, BioTek

In recognition of March being Bleeding Disorders Awareness Month , BioTek reMEDys , a multi-site national integrated infusion therapy provider focused on providing support to people with rare diseases, is publicly calling for awareness of safe medication use and treatments for patients with bleeding disorders and conditions.

Key Points: 
  • In recognition of March being Bleeding Disorders Awareness Month , BioTek reMEDys , a multi-site national integrated infusion therapy provider focused on providing support to people with rare diseases, is publicly calling for awareness of safe medication use and treatments for patients with bleeding disorders and conditions.
  • “Bleeding Disorders Awareness Month is an opportunity and a reminder to advocate for education as a priority throughout the healthcare continuum as we work towards recognizing the challenging journey patients often have on the way to a correct diagnosis and treatment."
  • Each March, the community calls attention to inheritable blood and bleeding disorders during Bleeding Disorders Awareness Month.
  • To learn more about hemophilia, von Willebrand disease, rare factor disorders and other bleeding disorders, visit hemophilia.org .

Half year reported NPATA US$2 billion¹,² Up 13% at constant currency³

Retrieved on: 
Tuesday, February 13, 2024
Acquisition, Warfarin, CSL Behring, Depreciation, Research, Ministry, Messenger, CIDP, Marketing, CSL, Growth, Plasmapheresis, Primary immunodeficiency, Von Willebrand disease, Antibody, S&M, Immunodeficiency, ASX, Income tax, Haemophilia, HAE, Ministry of Health, CSL Vifor, Hereditary angioedema, Plasma, COVID, Patient, Webcast, Phase, Diagnosis, G&A, CC3, Pressure, CSL Limited, Vaccine

MELBOURNE, Australia, Feb. 13, 2024 /PRNewswire/ -- CSL Limited (ASX:CSL; USOTC:CSLLY) today announces a reported net profit after tax of $1.90 billion1 for the 6 months ended 31 December 2023, up 20% on a constant currency basis3. Underlying profit (NPATA) was $2.02 billion1,2, up 13% on a constant currency basis to $2.06 billion1,2,3.

Key Points: 
  • Underlying profit (NPATA) was $2.02 billion1,2, up 13% on a constant currency basis to $2.06 billion1,2,3.
  • Immunoglobulin (Ig) product sales of $2,757 million, increased 23%3 with strong growth recorded across all geographies driven by global plasma supply and patient demand.
  • HIZENTRA® (Immune Globulin Subcutaneous (Human), 20% Liquid) sales were up 18%3 driven by  patient diagnosis rates.
  • However, due to the seasonality of this business we anticipate it to post a loss in the second half of the fiscal year.

Half year reported NPATA US$2 billion¹,² Up 13% at constant currency³

Retrieved on: 
Tuesday, February 13, 2024
Acquisition, Warfarin, CSL Behring, Depreciation, Research, Ministry, Messenger, CIDP, Marketing, CSL, Growth, Plasmapheresis, Primary immunodeficiency, Von Willebrand disease, Antibody, S&M, Immunodeficiency, ASX, Income tax, Haemophilia, HAE, Ministry of Health, CSL Vifor, Hereditary angioedema, Plasma, COVID, Patient, Webcast, Phase, Diagnosis, G&A, CC3, Pressure, CSL Limited, Vaccine

MELBOURNE, Australia, Feb. 13, 2024 /PRNewswire/ -- CSL Limited (ASX:CSL; USOTC:CSLLY) today announces a reported net profit after tax of $1.90 billion1 for the 6 months ended 31 December 2023, up 20% on a constant currency basis3. Underlying profit (NPATA) was $2.02 billion1,2, up 13% on a constant currency basis to $2.06 billion1,2,3.

Key Points: 
  • Underlying profit (NPATA) was $2.02 billion1,2, up 13% on a constant currency basis to $2.06 billion1,2,3.
  • Immunoglobulin (Ig) product sales of $2,757 million, increased 23%3 with strong growth recorded across all geographies driven by global plasma supply and patient demand.
  • HIZENTRA® (Immune Globulin Subcutaneous (Human), 20% Liquid) sales were up 18%3 driven by  patient diagnosis rates.
  • However, due to the seasonality of this business we anticipate it to post a loss in the second half of the fiscal year.

Hemab Therapeutics Appoints Dr. Akshay Vaishnaw to Board of Directors and Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Thursday, January 4, 2024
Conference, Science, Partnership, Royal college, Research and development, Bleeding, Cardiff University, Translational medicine, Trial of the century, Doctor of Philosophy, Research, Therapy, Innovation, University, Chairperson, Factor VII deficiency, Von Willebrand disease, Biogen

The company also announced CEO Benny Sorensen, MD, PhD, will present an update on Hemab's progress and outlook for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, at 4:30 PM PST/7:30 PM EST.

Key Points: 
  • The company also announced CEO Benny Sorensen, MD, PhD, will present an update on Hemab's progress and outlook for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, at 4:30 PM PST/7:30 PM EST.
  • We welcome Akshay and the expertise he brings to Hemab and its mission."
  • "Akshay joins our Board at a time when his experience leading translational research, clinical development and delivering regulatory success will be invaluable," said Dr. Sorensen.
  • "I am thrilled to have his partnership and to bring his passion for science and commitment to building people-focused cultures to Hemab."

Human medicines European public assessment report (EPAR): Veyvondi, vonicog alfa, Date of authorisation: 31/08/2018, Revision: 9, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Patient, Medical Subject Headings, Marketing, Agency, INN, Allergy, ATC, Antibody, Plasma, Blood, DDAVP, International, Bleeding, Von Willebrand factor, Injection, Headache, Disease, Coagulopathy, Language, Hypersensitivity, European Medicines Agency, Von Willebrand disease, Select, Anatomy, IIA, VWD, Medical device

Human medicines European public assessment report (EPAR): Veyvondi, vonicog alfa, Date of authorisation: 31/08/2018, Revision: 9, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Veyvondi, vonicog alfa, Date of authorisation: 31/08/2018, Revision: 9, Status: Authorised

Pathway to Cures Announces Inaugural Fund Update

Retrieved on: 
Thursday, November 2, 2023
General Health, Fund Raising, Health, Foundation, Philanthropy, Knowledge, Von Willebrand disease, Organizational founder, VWD, Hope, Biotechnology, MD, Doctor of Philosophy, MBA, Research, Hemostasis, Tan, Science, Blood, Heavy menstrual bleeding, Woman, Investment, Desmopressin, Litre, Parent, Pharmaceutical industry, Management, Pathway

Pathway to Cures (P2C) held its inaugural fund meeting on Saturday, October 28th in Chicago, Illinois.

Key Points: 
  • Pathway to Cures (P2C) held its inaugural fund meeting on Saturday, October 28th in Chicago, Illinois.
  • Pathway to Cures, an affiliate of the National Bleeding Disorders Foundation (NBDF), is a venture philanthropy fund focused on investing in early-stage companies developing cures, therapies, or enabling technologies in support of the inheritable blood and bleeding disorders community.
  • “Transcutaneous auricular neurostimulation (tAN) is a non-invasive method demonstrating great promise for treating various diseases.
  • “We have reviewed 114 companies over the past few months, whose promising research will accelerate the treatments and cures for rare diseases in the years to come.

Pathway to Cures Announces Venture Investment in Five Liters

Retrieved on: 
Monday, October 16, 2023
Research, General Health, Pharmaceutical, Philanthropy, Fund Raising, Foundation, Clinical Trials, Science, Biotechnology, Other Philanthropy, Other Science, Health, VNS, MBA, Doctor of Philosophy, Litre, Indian Council of Medical Research, Bleeding, Anemia, Sickle cell disease, MD, Northwell Health, Injury, Von Willebrand disease, VWD, Electricity, Vagus nerve stimulation, Medical research, Desmopressin, Feinstein Institutes for Medical Research, Coagulopathy, Haemophilia, Scientific Advisory Group, Tan, Hemostasis, Nature Communications, Cyclic permutation, Blood, Vagus nerve, Patient, Pharmaceutical industry, Medical device, The New York Times, Cure, Pathway

Pathway to Cures (P2C) announced today its investment of $500,000 in Five Liters, a subsidiary of Spark Biomedical, to develop therapies for treating inheritable blood and bleeding disorders.

Key Points: 
  • Pathway to Cures (P2C) announced today its investment of $500,000 in Five Liters, a subsidiary of Spark Biomedical, to develop therapies for treating inheritable blood and bleeding disorders.
  • Pathway to Cures, an affiliate of the National Bleeding Disorders Foundation, is a venture philanthropy fund focused on early-stage companies developing cures, therapies, or enabling technologies in support of the inheritable blood and bleeding disorders community.
  • This significant milestone is made possible through Five Liters' collaboration with Northwell Health’s Feinstein Institutes for Medical Research in New York.
  • Dr. Recht is Chief Medical and Scientific Officer at both Pathway to Cures and the National Bleeding Disorders Foundation (NBDF) and chairs the Pathway to Cures Scientific Advisory Group.

Advancements in Hemophilia Treatment Propel Global Bleeding Disorders Market to New Heights by 2032 - ResearchAndMarkets.com

Retrieved on: 
Monday, October 2, 2023
General Health, Health, Cardiology, Online, Antifibrinolytic, Pharmacy technician, Bleeding, Pharmacotherapy, S.A, Bayer, Takeda Pharmaceutical Company, Haemophilia, Market, Octapharma, Pfizer, Novo Nordisk, Coagulopathy, Government, Hospital, CSL Limited, Von Willebrand disease, Patient, Developed country, Pharmacy, Blood, Distribution, Sanofi, Growth, Haemophilia A, Pharmaceutical industry, Dentistry, Birth control, Health care

This growth is driven by rapid advancements in bleeding disorder treatments, an increasing number of patients with hemophilia A, hemophilia B, and other bleeding disorders, and government initiatives to support hemophilia management.

Key Points: 
  • This growth is driven by rapid advancements in bleeding disorder treatments, an increasing number of patients with hemophilia A, hemophilia B, and other bleeding disorders, and government initiatives to support hemophilia management.
  • Bleeding disorders encompass a group of conditions characterized by abnormal bleeding due to deficiencies or dysfunction in certain clotting factors in the blood.
  • Several factors are contributing to the growth of the bleeding disorders market, including:
    Rapid advancements in bleeding disorder treatment.
  • North America holds a major share of the bleeding disorders market, while Asia-Pacific is expected to witness the highest CAGR.

Star Therapeutics Raises $90 Million Financing to Accelerate Its Pipeline of Novel Antibody Therapies and Growth of Its Portfolio Companies

Retrieved on: 
Tuesday, September 5, 2023
Biotechnology, Other Health, Health, Pharmaceutical, Clinical Trials, OrbiMed, QIA, General partnership, Partner (business rank), Doctor of Philosophy, Star, Von Willebrand disease, Patient, Hematology, Biology, Growth, Therapy, Qatar Investment Authority, Pharmaceutical industry, MD

Star Therapeutics , a biotechnology company interrogating novel biology to develop life-changing therapies, today announced the closing of an oversubscribed $90 million Series C financing to continue growth of its first-in-class antibody therapies and portfolio companies.

Key Points: 
  • Star Therapeutics , a biotechnology company interrogating novel biology to develop life-changing therapies, today announced the closing of an oversubscribed $90 million Series C financing to continue growth of its first-in-class antibody therapies and portfolio companies.
  • Including this Series C round, Star Therapeutics has raised over $190 million since inception to create numerous portfolio companies.
  • This novel therapy is being developed by Vega Therapeutics, a Star portfolio company focused on underserved blood disorders.
  • We look forward to supporting Star as it continues to be an innovation engine for transformative therapies."

Global Blood & Plasma Components Market Outlook 2023-2027 with Revenue Shares by Product, Application, End-user and Company - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 29, 2023
Health, Other Health, Emergent BioSolutions, Albumin, Bleeding, Prevalence, Accident, Neurogenesis, Antibody, RFID, Takeda Pharmaceutical Company, New York Blood Center, Cancer, Ageing, Emergent, Octapharma, Research, Coagulopathy, LFB, Organization, Plasma, Death, CSL Limited, Hemoglobinopathy, Von Willebrand disease, Patient, Blood, Hematology, Growth, Conditional sentence, WHO, Blood volume, Haemophilia A, Trauma, Blood product, Pharmaceutical industry

The Global Blood & Plasma Components Market Outlook 2023-2027 report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The Global Blood & Plasma Components Market Outlook 2023-2027 report has been added to ResearchAndMarkets.com's offering.
  • The global blood & plasma components market is poised for impressive growth within the forecast period of 2023-2027.
  • The increasing occurrence of these situations significantly bolsters the global blood and plasma component market.
  • The global blood & plasma components market is categorized based on products, applications, end-users, and companies.